"A group of industry leaders warned on Tuesday that the artificial intelligence technology they were building might one day pose an existential threat to humanity and should be considered a societal risk on a par with pandemics and nuclear wars." We write this letter as humbly as a collection of overeducated and overcompensated executives can, in the hope that you will hear our cries and do something about A.I. before it's too late. Humanity is in grave danger of becoming extinct, and we--the world's most prominent A.I. researchers and executives who got us into this mess--are (wait for it) writing a letter. We are writing this very letter in order to: 1) show you how serious we are about writing letters, and 2) demonstrate how capable we are in our letter-writing skills. Also, this letter serves as a warning that the human race will definitely be wiped out because of the humanlike A.I. systems that the undersigned are responsible for developing and releasing into the world.

Using AI, researchers and executives can evaluate which areas of study have the best chance of translating to clinical trials. Artificial intelligence may be making more inroads into how scientific research is conducted, with a new tool able to predict which research projects are most likely to move to a clinical trial. The model, developed by colleagues at the Office of Portfolio Analysis (OPA), a part of the National Institutes of Health (NIH) responsible for evaluating and prioritizing research, aims to reduce the period of time between discovery and clinical application with an'Approximate Potential to Translate' (APT) metric. This metric utilizes the OPA's massive open citation collection, which consists of over 420 million citation links, to provide a highly accurate APT value. From this, researchers and executives can evaluate which areas of study have the best chance of translating to clinical trials, and which are likely to sit unused for decades.